MICA: A New Immune Response Gene That Predicts Kidney Transplant Failure

Histological image of a kidney transplant rejection mediated by antibodies. Sophie Caillard/Jérome Olagne (Inserm U1109).

Although a kidney transplant is the only curative treatment for end-stage kidney disease, the risk of the patient’s body rejecting the graft means that success is not guaranteed. To reduce this risk, physicians are now able to look at a certain number of genetic and immunological parameters in order to evaluate the histocompatibility between donor and recipient – i.e. how compatible their organs and tissues are. Nevertheless, rejections continue to remain common, and many are unexplained. In a new study, researchers from Inserm, Université de Strasbourg and Strasbourg University Hospitals at Unit 1109 “Molecular Immunology and Rheumatology”, and their partners from the Laboratory of Excellence (LabEx) Transplantex, report that the MICA gene is a new histocompatibility gene, in that it helps to better explain and predict the success or failure of a kidney transplant. Their findings have been published in Nature Medicine.

Kidney transplant is currently the best way to treat patients with end-stage kidney disease. In France, an average of around 4,000 kidney transplants are performed each year (around 20,000 in the US). The kidneys mainly come from deceased donors, although the number of kidneys from living donors has been gradually increasing each year over the last two decades.

The possibility of rejection of the graft considered “foreign” by the recipient’s body is currently the main limitation of this procedure. While the use of immunosuppressant drugs[1] helps to reduce the risk, it does not eliminate it completely. “Chronic” rejection, which occurs over the years following the transplant, remains a major problem.

The discovery of the HLA system in the mid-20th century by French researcher Jean Dausset and his colleagues has enabled major advances. It is a set of proteins coded by the HLA genes – proteins which are present on the surface of our cells, particularly white blood cells.

Highly diverse and specific to each individual, this system makes it possible to assess the histocompatibility between donors and recipients – i.e. how compatible their organs and tissues are. The closer the HLA genes between donors and recipients, the lower the risk of rejection.

However, even when donor and recipient HLA genes are compatible, unexplained transplant rejections still occur. This phenomenon suggests that other as yet unidentified histocompatibility genes may play a role.

A role for the MICA gene

Researchers from Inserm, Université de Strasbourg and Strasbourg University Hospitals and their partners from LabEx Transplantex were therefore interested in a gene discovered almost thirty years ago by Seiamak Bahram[2] who coordinated this new research.

This gene, called MICA, codes for a protein expressed on several cell types. Previous studies had already suggested that this gene was important in predicting the outcome of a transplant, but the numbers of patients studied were insufficient (among other methodological limitations) in asserting that it was a histocompatibility gene. Furthermore, these studies did not focus on the entire MICA system, that is to say on both genetics (histocompatibility) and the serological aspects (presence of anti-MICA antibodies in the recipient’s blood).

In this latest study, the team studied MICA in over 1,500 kidney transplant recipients and their donors. Analyses of the MICA gene sequences show that when recipients and donors have a different version of the gene, the survival of the graft is reduced.

Furthermore, the researchers show that these MICA gene incompatibilities are responsible for the synthesis of antibodies directed against the donor’s MICA proteins, which are involved in transplant rejection. These antibodies are produced when the donor’s MICA proteins differ excessively from those of the recipient.

These findings suggest that MICA is a relevant histocompatibility gene to consider when envisaging a transplant, and that testing for anti-MICA antibodies may also be useful in predicting the success or failure of the graft. They must now be validated in large-scale prospective studies in which MICA will be considered in the same way as classic HLA genes.

“Following this research, we can now consider the inclusion in routine clinical practice of MICA gene sequencing and the identification of anti-MICA antibodies in patients prior to transplantation to assess histocompatibility with the donor and post-transplant to improve the prevention of rejection. Finally, we also envisage studying the role of MICA in the transplantation of other solid organs, such as the heart, lung and liver,” emphasizes Seiamak Bahram.

[1] Treatments that limit the action of the immune system used in autoimmune diseases and transplants.

[2] University Professor-Hospital Practitioner, Director of Inserm Unit 1109 and LabEx Transplantex, and Head of the Department of Clinical Immunology Laboratory at Strasbourg University Hospitals.

These contents could be interesting :

Scientists discover novel mutation associated with alternating hemiplegia of childhood

Des scientifiques du Trinity College de Dublin, de l’Inserm, d’Université Paris Cité et de l’AP-HP au sein de l'Institut Imagine à l'hôpital Necker, à Paris, viennent de découvrir un....

Women and Parkinson’s Disease: Physical Activity Found to Be Beneficial More Than Twenty Years Before Diagnosis

Researchers from Inserm, Université Paris-Saclay and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ) with the Gustave Roussy Institute studied the impact of physical activity on the development of PD in nearly 100,000....

Medias

Researcher Contact

Seiamak Bahram

U1109 Immunologie et rhumatologie moléculaire (Inserm/Université de Strasbourg)

Email : rf.artsinu@kamais

Téléphone : 03.68.85.39.92

Seiamak Bahram

U1109 Immunologie et rhumatologie moléculaire (Inserm/Université de Strasbourg)

Email : rf.artsinu@kamais

Téléphone : 03.68.85.39.92

Press Contact

rf.mresni@esserp

Sources

The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation

Raphael Carapito^1,2,3,4,5, Ismail Aouadi^1,2,3,5, Martin Verniquet^1,2,3,5, Meiggie
Untrau^1,2,3,5, Angélique Pichot^1,2,3,5, Thomas Beaudrey^1,2,5,6, Xavier Bassand^1,2,5,6 Sébastien Meyer^1,2,3,5, Loic Faucher^2,7, Juliane Posson⁸, Aurore Morlon^2,9, Irina Kotova^2,9, Florent Delbos^2,10, Alexandre Walencik^2,10, Alice Aarnink¹¹, Anne Kennel1^1,7 Caroline Suberbielle^2,12, Jean-Luc Taupin^2,12, Benedict M. Matern¹³, Eric Spierings^13,8 Nicolas Congy-Jolivet^2,14, Arnaud Essaydi¹⁵, Peggy Perrin^1,2,5,6, Antoine Blancher^2,14,Dominique Charron^2,5,12, Nezih Cereb¹⁶, Myriam Maumy-Bertrand^2,5,17, Frédéric Bertrand^2,5,17, Valérie Garrigue^2,18, Vincent Pernin^2,18, Laurent Weekers¹⁹, Maarten Naesens²⁰, Nassim Kamar^2,21, Christophe Legendre^2,22, Denis Glotz^2,8, Sophie Caillard^1,2,5,6, Marc Ladrière²³, Magali Giral^2,7, Dany Anglicheau^2,22,24, Caner13 Süsal^25,26, Seiamak Bahram^1,2,3,4,5

1 Laboratoire d’ImmunoRhumatologie Moléculaire, Institut national de la santé et de
la recherche médicale (Inserm) UMR_S1109, Plateforme GENOMAX, Faculté de26
Médecine, Fédération Hospitalo-Universitaire OMICARE, Centre de Recherche
d’Immunologie et d’Hématologie, Centre de Recherche en Biomédecine de
Strasbourg (CRBS), Fédération de Médecine Translationnelle de Strasbourg (FMTS),
Université de Strasbourg, Strasbourg, France.

2 Laboratoire d’Excellence (LabEx) TRANSPLANTEX, Faculté de Médecine
Université de Strasbourg, Strasbourg, France.

3 Institut national de la santé et de la recherche médicale (INSERM) Franco
(Strasbourg)-Japanese (Nagano) Nextgen HLA laboratory, Strasbourg, France.

4 Laboratoire d’Immunologie, Plateau Technique de Biologie, Pôle de Biologie
Nouvel Hôpital Civil, Strasbourg, France.

5 Institut Thématique Interdisciplinaire (ITI) de Médecine de Précision de Strasbourg
Strasbourg, France.

6 Nephrology-Transplantation Department, University Hospital, Strasbourg, France.

7 CHU Nantes, Université de Nantes, INSERM, Centre de Recherche en
Transplantation et Immunologie, UMR 1064, ITUN, F-44000 Nantes, France.

8 Paris Translational Research Center for Organ Transplantation, Institut national de
la santé et de la recherche médicale (INSERM), UMR_S 970, Paris, France. Kidney
Transplant Department, Saint-Louis Hospital, Assistance Publique – Hôpitaux de
Paris, Paris, France.

9 BIOMICA SAS, Strasbourg, France.

10 Etablissement Français du Sang (EFS) Centre Pays de la Loire, Laboratoire HLA
Nantes, France.

11 Laboratory of Histocompatibility, Centre Hospitalier Régional Universitaire, Nancy,
France.

12 Laboratoire Jean Dausset, Laboratoire d’immunologie et d’histocompatibilité
Institut national de la santé et de la recherche médicale (Inserm) UMR_S 976
Human Immunology, Pathophysiology, Immunotherapy (HIPI), Institut de Recherche
Saint-Louis Université de Paris, Hôpital Saint-Louis, Paris, France.

13 Center of Translational Immunology, HLA and Tissue Typing, University Medical
Center Utrecht, Utrecht, The Netherlands.

14 Laboratoire d’immunogénétique moléculaire (LIMT, EA 3034), Faculté de
médecine Purpan, Université Toulouse 3 (Université Paul Sabatier, UPS), Toulouse
France. Laboratoire d’immunologie, Centre Hospitalier Universitaire de Toulouse,
France.

15 Etablissement Français du Sang (EFS) Grand-Est, Laboratoire HLA, Strasbourg
France.

16 Histogenetics, 300 Executive Blvd, Ossining, NY 10562.

17 Institut de Recherche Mathématique Avancée (IRMA), Centre national de la
recherche scientifique (CNRS) UMR 7501, Laboratoire d’Excellence (LabEx) Institut
de Recherche en Mathématiques, Interactions et Applications (IRMIA), Université de
Strasbourg, 67084, Strasbourg, France.

18 Service de Néphrologie-Transplantation-Dialyse péritonéale, Centre Hospitalier
Universitaire Lapeyronie, Montpellier, France.

19 Division of Nephrology, University of Liege Hospital (ULiege CHU), Liege,
Belgium.

20 Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium

21 Departments of Nephrology and Organ Transplantation, Centre Hospitalier
Universitaire de Rangueil, INSERM UMR1291 – CNRS UMR5051 – Université
Toulouse III, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity)
Toulouse, Université Toulouse III Paul Sabatier, Toulouse, F-31300 France.

22 Service de Transplantation Rénale Adulte, Hôpital Necker, Assistance Publique
Hôpitaux de Paris, Université de Paris, Paris, France.

23 Department of Renal Transplantation, Centre Hospitalier Régional Universitaire
Nancy, France.

24 Institut national de la santé et de la recherche médicale (INSERM), UMR_S 1151
Paris, France.

25 Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany

26 Transplant Immunology Research Center of Excellence, Koç University, Istanbul
Turkey.

Nature Medicine, mars 2022

DOI : https://www.nature.com/articles/s41591-022-01725-2

The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation